Correspondence 0001558370-24-005353 from MetaVia Inc. (MTVA)
MetaVia Inc.
Date: April 19, 2024 · CIK: 0001638287 · Accession: 0001558370-24-005353
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278646
Letter
L-120P (Audit Engagement - Public Co).docx
April 19, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street, NE
Washington, D.C. 20549
Attention: Dan Crawford
Re:NeuroBo Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-278646
Acceleration Request
Requested Date:April 23, 2024
Requested Time:5:30 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-278646) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence, Samuel Katz and Rachel Rhodes of Honigman LLP, counsel to the Company, to make such request on its behalf.
Please confirm the effectiveness of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702, Samuel Katz of Honigman LLP by telephone at (313) 465-8137 or Rachel Rhodes of Honigman LLP by telephone at (313) 465-7977.
Sincerely,
Show Raw Text
CORRESP 1 filename1.htm L-120P (Audit Engagement - Public Co).docx April 19, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street, NE Washington, D.C. 20549 Attention: Dan Crawford Re:NeuroBo Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-278646 Acceleration Request Requested Date:April 23, 2024 Requested Time:5:30 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rules 460 and 461 under the Securities Act of 1933, as amended, NeuroBo Pharmaceuticals, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on Form S-3 (File No. 333-278646) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above, or as soon as practicable thereafter, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. The Company hereby authorizes each of Phillip Torrence, Samuel Katz and Rachel Rhodes of Honigman LLP, counsel to the Company, to make such request on its behalf. Please confirm the effectiveness of the Registration Statement with Phillip Torrence of Honigman LLP by telephone at (269) 337-7702, Samuel Katz of Honigman LLP by telephone at (313) 465-8137 or Rachel Rhodes of Honigman LLP by telephone at (313) 465-7977. Sincerely, NEUROBO PHARMACEUTICALS, INC. /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer cc: Phillip D. Torrence, Honigman LLP Samuel Katz, Honigman LLP Rachel Rhodes, Honigman LLP NeuroBo Pharmaceuticals, Inc. 545 Concord Avenue, Suite 201 Cambridge, MA 02138 857.702.9600 info@neurobopharma.com